Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GZMO -- Ignore unavailable to you. Want to Upgrade?

To: jeffbas who wrote (49)	5/20/1999 5:59:00 PM
From: Heat Shock	Read Replies (1) \| Respond to of 438

To all: there is bad news about GZMO's joint venture with StressGen Biotechnologies (Yahoo quote SSB.TO) in Stressgen's annual report: In our joint venture with Genzyme Molecular Oncology, we were disappointed with the scientific results generated during 1998. We discovered weaknesses in our initial product candidate for ovarian cancer and therefore could not justify going into clinical development. Instead, we have identified another compound that we believe may be better suited for development. Testing of this compound will be completed by the second quarter of 1999. At that time, the joint venture will make a decision as to how to proceed with the gene therapy program. A discussion with Stressgen IR verified that not only the indication but the modality is under review. In Stressgen's annual report, they list Prostate cancer and "Melanoma Gene Therapy" as programs under way. A GZMO PR, biz.yahoo.com mentions these upcoming clinical trials: a phase I/II trial in melanoma, and phase I trials in breast cancer and ovarian cancer. Stressgen's lead product, HspE7 against cervical dysplasia, is in phase I. Heat.